Pavel Bogomolov
A5030437694- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Hepatitis Viruses Studies and Epidemiology
- Diet, Metabolism, and Disease
- Helicobacter pylori-related gastroenterology studies
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- Liver Diseases and Immunity
- Lipid metabolism and disorders
- Neurological Disorders and Treatments
- Chronic Lymphocytic Leukemia Research
- Cytomegalovirus and herpesvirus research
- Alcohol Consumption and Health Effects
- Veterinary medicine and infectious diseases
- COVID-19 Clinical Research Studies
- Gastroesophageal reflux and treatments
- Cancer Treatment and Pharmacology
- Metabolism, Diabetes, and Cancer
- Drug-Induced Hepatotoxicity and Protection
- Viral Infections and Immunology Research
- HIV/AIDS drug development and treatment
- SARS-CoV-2 and COVID-19 Research
- Medicinal Plants and Bioactive Compounds
- Colorectal Cancer Treatments and Studies
Regional Clinical Research
2015-2025
Moscow Regional Research Institute of Obstetrics and Gynecology
2016-2025
Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky
2015-2024
Target (United States)
2024
Université Paris Cité
2024
Centre de Recherche des Cordeliers
2024
Université Claude Bernard Lyon 1
2024
Assistance Publique – Hôpitaux de Paris
2024
Hôpital Cochin
2024
Centre de Recherche sur l'Inflammation
2024
Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated chronic B. Bulevirtide inhibits entry HDV into hepatocytes.In this ongoing phase 3 trial, patients D, or without compensated cirrhosis, were randomly assigned, in a 1:1:1 ratio, to receive bulevirtide subcutaneously at 2 mg per day (2-mg group) 10 (10-mg for 144 weeks no treatment 48 followed by 96 (control group). Patients will complete additional follow-up after end treatment. The primary point...
This study assessed the effects of glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to selective GLP-1 agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty disease (NAFLD).This was a phase IIa, randomized, active-comparator-controlled, parallel-group, open-label study. A magnetic resonance imaging-estimated proton density fraction assessment performed determine LFC at screening and Week 24. Participants an ≥10% were...
In a phase 3 trial, bulevirtide monotherapy led to virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label treatment for this disease. The role of combination therapy and peginterferon alfa-2a, particularly regard finite treatment, unclear.
Bulevirtide (BLV), a first-in-class entry inhibitor, is approved in Europe for the treatment of chronic hepatitis delta (CHD). BLV monotherapy was superior to delayed at week (W) 48, primary efficacy endpoint, MYR301 study (NCT03852719). Here, we assessed if continued therapy until W96 would improve virologic and biochemical response rates, particularly among patients who did not achieve W24.
ESR Endangered Species Research Contact the journal Facebook Twitter RSS Mailing List Subscribe to our mailing list via Mailchimp HomeLatest VolumeAbout JournalEditorsSpecials 31:119-145 (2016) - DOI: https://doi.org/10.3354/esr00749 FEATURE ARTICLE: REVIEW Dramatic global decrease in range and reproduction rate of European hamster Cricetus cricetus Alexey Surov1, Agata Banaszek2, Pavel Bogomolov1, Natalia Feoktistova1, Stefanie Monecke3,* 1Severtsov Institute Ecology Evolution, Russian...
Abstract Background Management of Helicobacter pylori ( H. ) infection requires co‐treatment with proton pump inhibitors (PPIs) and the use antibiotics to achieve successful eradication. Aim To evaluate role dosage PPIs duration therapy in effectiveness eradication treatments based on ‘European Registry management’ (Hp‐EuReg). Methods Hp‐EuReg is a multicentre, prospective, non‐interventionist, international registry routine clinical practice management by European gastroenterologists. All...
ABSTRACT Background and Aim Bulevirtide (BLV) leads to beneficial virologic biochemical responses when given alone treat hepatitis delta virus (HDV) infection, which causes the most severe form of chronic viral hepatitis. We evaluated 48 weeks BLV monotherapy, + tenofovir disoproxil fumarate (TDF) pegylated interferon alfa‐2a (Peg‐IFNα‐2a), with 24‐week follow‐up. Methods Ninety patients were enrolled into six arms 15 each (A–F); 60 included in main randomisation (arms A–D), 30 E–F)...
Abstract Background Bulevirtide (BLV) is a first-in-class entry inhibitor for chronic hepatitis D (CHD) approved in Europe. Interim results from MYR301 (NCT03852719), phase 3 randomized study, showed monotherapy with BLV 2 mg/d or 10 given subcutaneously was effective and safe over 144 weeks (W). With greater risk of developing cirrhosis HDV than HBV alone, we explore the impact status on efficacy safety through 144W.Table 1.Efficacy at Week based Methods 150 patients CHD were stratified...
Abstract Background Chronic Hepatitis Delta (CHD) is the most severe form of viral hepatitis. Bulevirtide (BLV) a first-in-class entry inhibitor approved in EU for treatment compensated CHD. In MYR204, Phase 2b study evaluating finite with BLV or without pegylated interferon alfa-2a (Peg-IFNa), combination 10mg resulted higher undetectable HDV RNA rates 24 weeks (W) post end (EOT) compared either monotherapy regimen. Here, we present predictors at 48W (FU-48) post-EOT.Table 1.Comparison Key...
Aim . The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care patients with non-alcoholic fatty liver disease, taking into account latest data principles evidence-based medicine. Key points Clinical contain about current views on etiology, risk factors pathogenesis nonalcoholic peculiarities its course. Also given recommendations methods laboratory...